Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Keck

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Journal of Hematology & Oncology|May 15, 2009
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndromeAzra Raza, Naomi Galili, Natalie Callander, et al.
Journal of Medicinal Chemistry|September 17, 2004
Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprintsNancy Hsu, Danying Cai, Komath Damodaran, et al.
The Journal of Infectious Diseases|May 9, 2017
Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological InfectionJessica R Spengler, M Kelly Keating, Anita K McElroy, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 27, 2010
Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancerIgnace Vergote, Neil J Finkler, James B Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignanciesLee S Rosen, Joseph Brown, Bernadette Laxa, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 23, 2023
Simultaneous evaluation of treatment efficacy and toxicity for bispecific T-cell engager therapeutics in a humanized mouse modelJiwon Yang, Jing Jiao, Kyle M Draheim, et al.
Journal of Medicinal Chemistry|September 16, 2008
Design, synthesis, and structure-activity relationships of novel insulin receptor tyrosine kinase activatorsRobert T Lum, Mingshan Cheng, Cristina P Cristobal, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 18, 2017
Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapyMinan Wang, Li-Chin Yao, Mingshan Cheng, et al.
Molecular Cancer Therapeutics|February 28, 2018
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2009
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancerLecia V Sequist, Panos M Fidias, Jennifer S Temel, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Journal of Hematology & Oncology|May 15, 2009
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndromeAzra Raza, Naomi Galili, Natalie Callander, et al.
Journal of Medicinal Chemistry|September 17, 2004
Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprintsNancy Hsu, Danying Cai, Komath Damodaran, et al.
The Journal of Infectious Diseases|May 9, 2017
Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological InfectionJessica R Spengler, M Kelly Keating, Anita K McElroy, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 27, 2010
Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancerIgnace Vergote, Neil J Finkler, James B Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignanciesLee S Rosen, Joseph Brown, Bernadette Laxa, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 23, 2023
Simultaneous evaluation of treatment efficacy and toxicity for bispecific T-cell engager therapeutics in a humanized mouse modelJiwon Yang, Jing Jiao, Kyle M Draheim, et al.
Journal of Medicinal Chemistry|September 16, 2008
Design, synthesis, and structure-activity relationships of novel insulin receptor tyrosine kinase activatorsRobert T Lum, Mingshan Cheng, Cristina P Cristobal, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 18, 2017
Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapyMinan Wang, Li-Chin Yao, Mingshan Cheng, et al.
Molecular Cancer Therapeutics|February 28, 2018
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2009
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancerLecia V Sequist, Panos M Fidias, Jennifer S Temel, et al.
Pageof 8